Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors
- PMID: 3286766
Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors
Abstract
Tumor-infiltrating lymphocytes (TIL) were obtained from human ovarian tumors, expanded in the presence of IL-2 in culture and studied for cytotoxicity against fresh autologous and allogeneic ovarian carcinoma (CA) targets. TIL from ovarian tumors grew well in long term cultures, achieving from 8- to 682-fold expansion. TIL cultured with IL-2 were cytotoxic against both autologous and allogeneic fresh ovarian CA targets, and no specificity for autologous tumor could be demonstrated in any of the cultures. In all fresh TIL preparations, CD3+ lymphocytes were the major cell type and contained a high proportion (up to 51%) of activated (IL-2R+) cells as determined by two-color flow cytometry. Sorting of bulk TIL cultures followed by cytotoxicity assays identified the Leu-19+ cells, both CD3+ and CD3-, as effectors of cytotoxicity against autologous and allogeneic tumor cell targets. Cold target inhibition assays showed that allogeneic targets (both ovarian CA and a sarcoma) competed effectively with autologous ovarian CA targets for Leu-19+ effectors in TIL cultures. mAb to Leu-19 or Leu-2a did not block lysis of autologous targets by sorted effectors. OKT3 antibody augmented lysis of autologous targets by CD3+Leu-19- effectors only. These results show that non-MHC-restricted Leu-19+ effectors in cultures of TIL with 1000 U/ml of rIL-2 mediate lysis of autologous and allogeneic tumor cells. The CD3+Leu-19- cells, the main population in these cultures, do not mediate tumor lysis. To determine the phenotype of antitumor effectors in IL-2 cultures of TIL, cell sorting followed by functional assays are necessary.
Similar articles
-
Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.Cancer Res. 1989 Nov 1;49(21):5979-85. Cancer Res. 1989. PMID: 2507139
-
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.Cancer Res. 1988 Jan 1;48(1):206-14. Cancer Res. 1988. PMID: 3257161
-
Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.J Immunol. 1989 Nov 15;143(10):3404-11. J Immunol. 1989. PMID: 2509557
-
Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.Nat Immun Cell Growth Regul. 1990;9(4):253-64. Nat Immun Cell Growth Regul. 1990. PMID: 2215514 Review.
-
Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.Fed Proc. 1986 Nov;45(12):2823-8. Fed Proc. 1986. PMID: 3095151 Review.
Cited by
-
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.Front Immunol. 2019 Aug 9;10:1782. doi: 10.3389/fimmu.2019.01782. eCollection 2019. Front Immunol. 2019. PMID: 31456796 Free PMC article. Review.
-
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma.Clin Pharmacol. 2013 May 23;5(Suppl 1):13-9. doi: 10.2147/CPAA.S40401. Print 2013. Clin Pharmacol. 2013. PMID: 23723721 Free PMC article.
-
Interferon beta enhances the natural killer activity of patients with bladder carcinoma.Cancer Immunol Immunother. 1994 Jun;38(6):406-10. doi: 10.1007/BF01517211. Cancer Immunol Immunother. 1994. PMID: 8205562 Free PMC article.
-
Tumor-infiltrating lymphocytes from nonrenal urological malignancies.Cancer Immunol Immunother. 1990;30(6):342-50. doi: 10.1007/BF01786883. Cancer Immunol Immunother. 1990. PMID: 2105845 Free PMC article.
-
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.Cancer Immunol Immunother. 1992;34(4):241-51. doi: 10.1007/BF01741792. Cancer Immunol Immunother. 1992. PMID: 1311218 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials